Approval · Notice of Compliance 25430 · 2021
RAN-OXYCODONE CR: Notice of Compliance 25430
Issued March 12, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25430
- Date
- March 12, 2021
- Company
- Ranbaxy Pharmaceuticals Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to product monograph
- Canadian reference product
- OXYCONTIN (Purdue Pharma)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RAN-OXYCODONE CR | Not yet assigned | — |
Medicinal ingredients
- OXYCODONE HYDROCHLORIDE 20 MG per UNIT
- OXYCODONE HYDROCHLORIDE 40 MG per UNIT
- OXYCODONE HYDROCHLORIDE 60 MG per UNIT
- OXYCODONE HYDROCHLORIDE 80 MG per UNIT
- OXYCODONE HYDROCHLORIDE 15 MG per UNIT